Table 4.
Percentages of hemodialysis and peritoneal dialysis patients prescribed specific blood pressure medications within frequently prescribed classes,* 2007–2008
| |
Hemodialysis patients |
Peritoneal dialysis patients |
||
|---|---|---|---|---|
| Class and medication | Class | Agent | Class | Agent |
| Beta blockers |
65.6 |
|
60.4 |
|
| Metoprolol succinate |
|
25.5 |
|
32.8 |
| Metoprolol tartrate |
|
27.7 |
|
25.8 |
| Carvedilol (alpha-beta blocker) |
|
24.7 |
|
22.7 |
| Atenolol |
|
11.0 |
|
7.8 |
| Labetalol (alpha-beta blocker) |
|
9.1 |
|
7.0 |
| % of class represented |
|
98.0 |
|
96.1 |
| ACEIs |
31.4 |
|
39.6 |
|
| Lisinopril |
|
66.6 |
|
60.7 |
| Enalapril |
|
9.7 |
|
1.2 |
| Benazepril |
|
9.5 |
|
16.7 |
| Ramipril |
|
4.6 |
|
7.1 |
| Fosinopril |
|
4.4 |
|
4.8 |
| Quinapril |
|
4.3 |
|
7.1 |
| % of class represented |
|
99.1 |
|
97.6 |
| ARBs |
17.0 |
|
23.1 |
|
| Valsartan |
|
40.4 |
|
36.7 |
| Losartan |
|
31.4 |
|
38.7 |
| Irbesartan |
|
11.0 |
|
8.2 |
| Olmesartan |
|
9.2 |
|
4.1 |
| Telmisartan |
|
5.3 |
|
8.2 |
| Candesartan |
|
2.7 |
|
4.1 |
| % of class represented |
|
100 |
|
100 |
| DHP-CCBs |
43.4 |
|
39.2 |
|
| Amlodipine |
|
66.2 |
|
61.4 |
| Nifedipine |
|
23.2 |
|
21.7 |
| Felodipine |
|
5.6 |
|
8.4 |
| Nisoldipine |
|
4.0 |
|
4.8 |
| % of class represented |
|
99.0 |
|
96.3 |
| Loop diuretics |
29.2 |
|
45.3 |
|
| Furosemide |
|
84.7 |
|
89.6 |
| Bumetanide |
|
10.4 |
|
6.3 |
| Torsemide |
|
4.9 |
|
4.2 |
| % of class represented |
|
100 |
|
100 |
| Central alpha 2 agonist |
19.5 |
|
12.3 |
|
| Clonidine |
|
98.9 |
|
96.2 |
| Methyldopa |
|
0.8 |
|
3.8 |
| % of class represented |
|
99.7 |
|
100 |
| Alpha blockers |
6.6 |
|
11.8 |
|
| Doxazosin |
|
63.5 |
|
68.0 |
| Terazosin |
|
33.8 |
|
32.0 |
| Prazosin |
|
2.7 |
|
0.0 |
| % of class represented |
|
100 |
|
100 |
| Hydralazine |
11.1 |
|
4.7 |
|
| % of class represented | 100 | 100 | ||
Note: Values are percentages.
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; DHP-CCB, dihydropyridine calcium channel blocker.
*Prescribed in at least 10% of hemodialysis or peritoneal dialysis patients at month 6 after dialysis initiation.